DAVID SLACK

David serves as an independent director for DrugCenR. He currently alsoserves as Chief Business Officer for Viracta Therapeutics, a private,clinical-stage company developing novel treatments for virus-associatedcancers. David has served as Head of Corporate Development for Swiss-basedNovimmune SA; CEO of Kinagen, Inc.; Vice President of Business Developmentfor publicly listed Ionis Pharmaceuticals; and in senior roles atRhone-Poulenc Rorer and Aventis Pharma. His deal-making experience exceeds$1 billion in transactions, encompassing major corporate partnerships,spin-outs, start-ups, and financings. David has provided corporatedevelopment, partnering, investment and drug commercialization advisoryservices to a range of organizations.